Axsome Therapeutics (AXSM) Net Cash Flow (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -662.16% |
| Dec 31, 2025 | -110.51% |
| Sep 30, 2025 | 956.79% |
| Jun 30, 2025 | 114.58% |
| Mar 31, 2025 | -20.48% |
| Dec 31, 2024 | -202.60% |
| Sep 30, 2024 | 174.02% |
| Jun 30, 2024 | 71.17% |
| Mar 31, 2024 | -80.28% |
| Dec 31, 2023 | -47.80% |
| Sep 30, 2023 | -110.78% |
| Jun 30, 2023 | 317.31% |
| Mar 31, 2023 | 271.20% |
| Dec 31, 2022 | -117.31% |
| Sep 30, 2022 | 1,462.26% |
| Jun 30, 2022 | -541.02% |
| Mar 31, 2022 | 93.73% |
| Dec 31, 2021 | -5.84% |
| Sep 30, 2021 | -13.46% |
| Jun 30, 2021 | -21.99% |
| Mar 31, 2021 | -3.96% |
| Dec 31, 2020 | -258.28% |
| Sep 30, 2020 | 276.11% |
| Jun 30, 2020 | 70.73% |
| Mar 31, 2020 | -112.85% |
| Dec 31, 2019 | 1,843.84% |
| Sep 30, 2019 | -190.76% |
| Jun 30, 2019 | -61.12% |
| Mar 31, 2019 | 2,388.76% |
| Dec 31, 2018 | 75.60% |
| Sep 30, 2018 | 18.32% |
| Jun 30, 2018 | 14.99% |
| Mar 31, 2018 | -414.70% |
| Dec 31, 2017 | 137.14% |
| Sep 30, 2017 | 10.02% |
| Jun 30, 2017 | -183.62% |
| Mar 31, 2017 | 207.66% |
| Dec 31, 2016 | 155.97% |
| Sep 30, 2016 | 8.40% |
| Jun 30, 2016 | -34.56% |
| Mar 31, 2016 | -109.12% |
| Dec 31, 2015 | 2,520.83% |
| Sep 30, 2015 | -137.97% |
| Jun 30, 2015 | 609.37% |